-
completion of additional capital investment of $140 million by As AstraZeneca, Before announced upon November 1st and 15, 2023
NEW YORK, May 6, 2024 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today announced: , after receiving approval from the French Ministry of Economy and meeting all other closing conditions, AstraZeneca (LSE/STO/Nasdaq: AZN) will be announced on November 1 and 15, 2023, as previously announced by Cellectis. , completed his $140 million additional equity investment in Cellectis. (“”additional investment”).
As part of the follow-on investment, AstraZeneca today announced 10 million ‘Class A’ convertible preference shares and 18 million ‘Class B’ convertible preference shares issued by the Cellectis Board of Directors, each at a price of $5.00 per convertible preference share. I accepted it. Based on the approval granted by the Extraordinary General Meeting of Cellectis to be held on December 22, 2023.
Prior to conversion into common stock, “Class A” convertible preferred stock has single voting rights and cannot have double voting rights under any circumstances. In addition, “Class B” convertible preferred stock does not have voting rights except as follows: Distribution of Dividends or Reserves. Both classes of preferred stock enjoy liquidation preference (if there is a liquidation surplus at par for all shareholders after repayment of Cellectis’ creditors) and, at AstraZeneca’s direction, have the same rights as preferred stock. Can be converted into the same number of common shares. Common Stock Outstanding.
Immediately after this additional investment, AstraZeneca will hold approximately 44% of the Company’s share capital and approximately 30% of the voting rights (based on the current number of outstanding voting rights).
In addition, it was decided at Cellectis’ special general meeting of shareholders to be held on December 22, 2023, and subject to the completion of additional resolutions, that Mr. Marc Dunoyer and Dr. Tyrell Rivers will be appointed as members of Cellectis’ Board of Directors. Ta. Your investment is now valid.
If no public offering is made, no prospectus will be drawn up in France or outside France in connection with the follow-on investment.
about Cellulectis
Cellectis is a clinical-stage biotechnology company using a pioneering gene editing platform to develop life-saving cell and gene therapies. Cellectis is leveraging an allogeneic approach to CAR-T immunotherapy in oncology, developing the concept of off-the-shelf, ready-to-use gene-edited CAR T cells to treat cancer patients and therapeutic gene editing in hematopoiesis. It is a pioneer of the platform that will make this possible. Stem cells are effective against various diseases. As a clinical-stage biopharmaceutical company with over 24 years of experience and expertise in gene editing, Cellectis utilizes TALEN®, a gene editing technology, and PulseAgile, a pioneering immune-powered electroporation system. and develop life-changing product candidates. A system for treating diseases with unmet medical needs. Cellectis is headquartered in Paris, France, with offices in New York, New York, and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
For more information about Cellectis, please contact:
media contact address:
Pascalyne Wilson, Director of Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor information contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, Life Sciences Advisor, +1 617 430 7577
attachment
